Analysts upgrade Best Buy, Lululemon, and Collegium Pharma, but downgrade Maxeon Solar and Medifast.

From Investing.com: 2024-06-09 05:07:19

Last week, Wall Street analysts upgraded Best Buy, Lululemon, and Collegium Pharma. However, Maxeon Solar and Medifast faced downgrades. Citi raised Best Buy’s price target to $100, citing tech replacement cycles and margin execution. On the flip side, Goldman Sachs double downgraded Maxeon Solar to Sell with a $1 price target due to weak guidance and capital restructuring. Medifast was downgraded to Underperform by DA Davidson due to revenue projections and delayed advertising campaigns. HSBC upgraded Lululemon to Buy with a $425 price target, noting concerns about North American growth. Jefferies upgraded Collegium Pharma to Buy with a $44 price target, citing strong 2Q trends and valuation factors.

Source: https://www.investing.com/pro/pricing/plans?view=marketing-pro-included&source=content&campaign=content_analysis&content=200645950&term=none



Read more at Investing.com: Upgrades for Best Buy and Lululemon By Investing.com